StockCode
688506
Investors
中文 | EN

Received provincial certification as the “Technological Innovation Exemplar Entity”

时间:2022-11-07

On November 3, 2022, Sichuan Provincial Economic and Information Department issued the Notice on Issuing the List of Technological Innovation Demonstration Enterprises in Sichuan Province in 2022. Sichuan Biokin Pharmaceuticals Co., Ltd., a core member of the group was recognized as Technological Innovation Demonstration Enterprise in Sichuan Province.

The recognition of technological innovation demonstration enterprise is an important initiative of the Ministry of Industry and Information Technology and local economic and information competent departments to implement the strategic deployment of the central government on building an innovative country, and to promote and improve the building of a technological innovation system with enterprise as main body, market as orientation and combination of industry, university and research institution. Technological Innovation Demonstration Enterprise refers to an enterprise with relatively strong technological innovation capability, remarkable innovation performance and important demonstration and leading role in the major industries. The provincial-level recognition of Biokin Pharmaceuticals is an embodiment of the governments further recognition for the enterprises innovation system construction and innovation achievements after the recognition of National Enterprise Technology Center, and is also the basis for the enterprise to apply for recognition of national technology innovation demonstration enterprise in the next step.

 



09ba7850-1bda-471c-baeb-734bcf8f545f.jpg




表格(改像素).jpg

Systimmune
Baili Pharmaceutical
Guorui Pharmaceutical
Baili-Bio
Jingxi Pharmaceutical
Hiatt Technology
Company Address:1#, Building 1,No.161, Baili Road, Cross-Strait Science and Technology Industrial Development Park, Wenjiang District, Chengdu City
Postcode:610041
Tel:028-85183639
Sichuan Biokin Pharmaceuticals Co.,Ltd Copyright © 2018 All rights reserved
SICPB No. 17035664-1   
Internet Drug Information Service Qualification Certificate S/N: (C)-FJYX-2022-0343